Head and Neck

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
24001
Randomized phase III study on the selection of the target volume in postoperative radiotherapy for cervical lymph node metastases of squamous cell carcinoma from an unknown primary (CUP)
24981
A feasibility study of primary chemotherapy followed by concomitant chemoradiation with or without amifostine in patients with locally advanced undifferenciated nasopharyngeal cancer (UNPC).
24982
Phase II study on Gemcitabine in Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck
22996
A phase III double-blind, randomized, placebo-controlled study of Erythropoietin when used as an adjuvant to radiation therapy in patients with head and neck squamous cell carcinoma. EORTC 22996-24002
24971
A randomized phase III multicenter trial of neoadjuvant docetaxel (Taxotere) plus cisplatin plus 5-fluorouracil versus neoadjuvant cisplatin plus 5-fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck
22962
A phase III study comparing conventional versus hyperfractionated radiotherapy, with or without concomitant chemotherapy, in patients with head and neck squamous cell carcinoma.
24954
Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy versus alternating chemo-radiotherapy in resectable hypopharynx and larynx cancers (Jointly with the EORTC Radiotherapy Cooperative Group)
22954
Phase III study on larynx preservation comparing radiotherapy versus concomitant chemo-radiotherapy in resectable hypopharynx and larynx cancers (Joint study of the Radiotherapy Cooperative Group and the Head and Neck Cancer Cooperative Group).
15941
An international field study of the reliability and validity of the EORTC QLQ-C30 (v. 3.0) and a diagnosis-specific module (the EORTC QLQ-H&N35) in assessing the quality of life of patients with head and neck cancer
04941
Phase II study of navelbine in patients with metastatic and/or local recurrent squamous cell carcinoma of the head and neck previously untreated by chemotherapy and with lesions within previously irradiated fields
04942
Phase II study of Navelbine in patients with metastatic and/or local recurrent squamous cell carcinoma of the head and neck previously untreated by chemotherapy and with lesions outside previously irradiated fields
24922
Randomized phase II trial of Methotrexate vs two schedules of Taxol in patients with advanced squamous cell carcinoma of the head and neck
22931
Phase III randomized study on postoperative radio- and chemotherapy in patients with locally advanced head and neck carcinomas (Joint study of the EORTC Radiotherapy Cooperative Group and the Head and Neck Cancer Cooperative Group)
22932
Phase III randomized study on the role of the booster dose of postoperative radiotherapy in patients with early stage carcinomas of head and neck (Jointly with the EORTC Radiotherapy Cooperative Group)
24921
Phase II study of Interferon alpha and 5-fluorouracil in locally advanced or recurrent or metastatic squamous cell carcinoma of the head and neck
22923
Accelerated radiotherapy with carbogen and nicotinamide. A phase I/II study
04912
Etude de phase II d'un nouveau dérivé du platine, le lobaplatine (SAR 540), dans les cancers avanc‚s des voies a‚ro-digestives sup‚rieures
04913
Etude de phase II d'un nouveau dérivé du platine, le lobaplatine (SAR 540), dans les cancers des voies a‚ro-digestives sup‚rieures r‚sistant au Cisplatine ou au carboplatine
24891
Is laryngeal preservation with induction chemotherapy safe in the treatment of hypopharyngeal squamous cell carcinoma ? A randomized phase III trial
04891
Essais cliniques phase II d'une nouvelle nitrosourée: la Cystémustine dans les poumons, les adénocarcinomes colo-rectaux, les gliomes, les mélanomes, les reins, les sarcomes des parties molles et les tumeurs de la tête et du cou.
16893H
Phase II trial of GR63178A in patients with squamous cell carconoma of the head and neck
24882
Phase II study of mitoxantrone in recurrent or metastatic adenoid cystic carcinoma of the head and neck
24881
Phase II study of Epirubicin and Cisplatin in advanced nasopharyngeal carcinoma (NFC)
24872
Randomized phase III trial of methotrexate vs 10-EdAm, a new methotrexate analogue,in patients with advanced squamous cell carcinoma of the head and neck
24871
EUROSCAN: Phase III randomized trial of chemoprevention with vitamin A and N-acetylcysteine in patients curatively treated for carcinomas of the larynx, oral cavity and lung. (Jointly with the EORTC Lung Cancer Cooperative Group : Protocol 08871)
16864C
Phase II Chemotherapy with Flavone Acetic Acid in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 03/88)
24861
Phase III Randomized Comparison of Chemotherapy with CDDP/5-FU Followed by Radiotherapy vs Radical Surgery with or without Radiotherapy in Patients with Nonmetastatic Squamous Cell Carcinoma of the Larynx
04861
Etude clinique phase II 4' -0-tetrahydropyranyl adriamycine (THP-ADM-1609 RB)
24863
Phase II Randomized Chemotherapy Trial of CHIP vs CACP in Patients with Advanced Ovarian Cancer Refractory or Recurrent After First-Line Chemotherapy with CBDCA (Summary Last Modified 05/88
24851
PHASE II STUDY OF 4'-EPIDoxorubicin IN RECURRENT OR METASTATIC ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK.
22851
Phase III trial of open accelerated fractionation vs conventional fractionation in the radiotherapy of advanced head and neck carcinoma
24844
5-FU/CDDP FOLLOWED BY SURGERY AND RADIOTHERAPY vs SURGERY AND RADIOTHERAPY IN ADVANCED SQUAMOUS CELL CARCINOMA OF LATERAL OROPHARYNX AND LATERAL POSTERIOR ORAL CAVITY (Phase III trial)
22843
Multiple fractions per day (MFD) or conventional fractionated irradiation in combination with cis-diammine dichloro platinium (II) (c-DDP) a randomized phase II study in advanced head and neck cancer.
24842
Randomized trial of cisplatin, methotrexate, bleomycin and vincristine (CABO) vs cisplatin and 5-fluorouracil (CF) vs cisplatine alone (C) in patients with advanced squamous cell carcinoma of the head and neck.
22791
Phase III trial of twice daily fractions versus single daily fraction radiotherapy in oropharyngeal carcinoma
24941
A randomized phase III study of supportive care plus Methotrexate versus supportive care only in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
90061
Multicenter parallel phase II trial of BI 2536 administrered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions (NOCI)
22071
Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence
11001
10B-uptake in different tumours using the boron compounds BSH and BPA.
24061
Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies
24051
Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell.
16008
Phase II study on NX 211(liposomal lurtotecan) given as an IV bolus injection on days 1 and 8 every 3 weeks in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck with target lesions within previously irradiated fields or outside previously irradiated fields.
16921H
Phase II trial with Taxotere in patients with squamous cell carcinoma of the head and neck
16901H
Phase II trial of Gemcitabine (LY 188011) in patients with squamous cell carcinoma of the head and neck

Back to Site-list